Janux Therapeutics, Inc. Common Stock (JANX)
PHARMACEUTICAL PREPARATIONS
Janux Therapeutics, Inc. Common Stock (JANX) is listed on Nasdaq, where it has traded since June 11, 2021.
- Listed On
- Nasdaq
- Listed Since
- June 11, 2021
- Employees
- 113
- Market Cap
- $1.1B
About Janux Therapeutics, Inc. Common Stock
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 189 institutions reported holding JANX, with 60.7 million shares worth $931.5 million in aggregate. The largest reported holder was RA Capital Management, with 11.2 million shares worth $171.9 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management | 11,189,693 | $172M | Unchanged |
| BlackRock | 6,134,667 | $94M | Added 12.91% |
| Prosight Management | 3,804,481 | $58M | Added 7.17% |
| Vanguard | 3,556,637 | $55M | Added 2.54% |
| State Street | 3,004,899 | $46M | Added 21.95% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is JANX?
Janux Therapeutics, Inc. Common Stock (JANX) is listed on Nasdaq, where it has traded since June 11, 2021.
Who are the largest institutional holders of JANX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of JANX were RA Capital Management, BlackRock and Prosight Management.
How many institutions own JANX?
189 institutions reported a position in JANX for the quarter ended June 30, 2026, worth $931.5 million in total.
Did institutions buy or sell JANX last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for JANX.
Every reported institutional holder, plus insider and congressional trades in JANX, on SentiSense.